ENDRA Life Sciences (NDRA) Common Equity (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Common Equity data on file, last reported at $1.8 million in Q1 2026.

• Common Equity for Q1 2026 came in at $1.8 million, up 1.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 1.94% YoY), and the FY2025 annual result was $2.3 million, down 11.73% from the prior year.
• Common Equity declined to $1.8 million in Q1 2026 per NDRA's latest filing, from $2.3 million in the prior quarter.
• Over five years, Common Equity peaked at $13.3 million in Q2 2022 and troughed at $171380.0 in Q3 2025.
• A 5-year average of $5.4 million and a median of $5.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity advanced 29.77% in 2024, then plunged 97.41% in 2025.
• A 5-year view of Common Equity shows it stood at $7.2 million in 2022, then retreated by 21.45% to $5.7 million in 2023, then tumbled by 54.76% to $2.6 million in 2024, then retreated by 11.73% to $2.3 million in 2025, then declined by 20.94% to $1.8 million in 2026.
• Business Quant data shows NDRA's Common Equity at $1.8 million in Q1 2026, $2.3 million in Q4 2025, and $171380.0 in Q3 2025.